IP Verse

Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist - EP2228064

The patent EP2228064 was granted to Novartis on Dec 11, 2019. The application was originally filed on May 17, 2005 under application number EP10164976A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2228064

NOVARTIS
Application Number
EP10164976A
Filing Date
May 17, 2005
Status
Granted And Under Opposition
Nov 8, 2019
Publication Date
Dec 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR SCHONSep 11, 2020SCHONADMISSIBLE
EUROPEAN OPPOSITIONSSep 11, 2020KILBURN & STRODEADMISSIBLE
HGFSep 11, 2020HGFADMISSIBLE
ISARPATENTSep 11, 2020ISARPATENTADMISSIBLE
NEDERLANDSCH OCTROOIBUREAUSep 11, 2020NEDERLANDSCH OCTROOIBUREAUADMISSIBLE
STADA ARZNEIMITTELSep 11, 2020HAMM & WITTKOPPADMISSIBLE
ORION ORION PHARMASep 11, 2020J A KEMPWITHDRAWN
PGASep 10, 2020PGAWITHDRAWN
HOFFMANN EITLESep 8, 2020HOFFMANN EITLEWITHDRAWN
TEVA PHARMACEUTICALSSep 8, 2020ELKINGTON AND FIFEWITHDRAWN

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONCA2368583
OPPOSITIONEP1755590
OPPOSITIONEP2228064
OPPOSITIONEP2778064
OPPOSITIONUS2002179087
OPPOSITIONUS2002193392
OPPOSITIONUS2004002548
OPPOSITIONUS6307060
OPPOSITIONUS6433027
OPPOSITIONUS6585958
OPPOSITIONUS6645466
OPPOSITIONWO0047200
OPPOSITIONWO0069468
OPPOSITIONWO0075114
OPPOSITIONWO0170198
OPPOSITIONWO0176575
OPPOSITIONWO0245703
OPPOSITIONWO2004017918
OPPOSITIONWO2005110402
OPPOSITIONWO2016046150
SEARCHUS2004002548
SEARCHWO0075114

Non-Patent Literature (NPL) Citations (94) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- A BACULARD, "Place du Bronchodual® dans le traitement de fond de 1’asthme de 1’enfant", Archives de Pédiatrie, (19950000), vol. 2, no. 2, pages 149 - 153, XP055732927
OPPOSITION- A.L. RIES et al., "what's new in COPD? The treatment options", The Journal of Respiratory Diseases, (20000000), vol. 21, no. 5, pages 304 - 320, XP055733087
OPPOSITION- Anonymous, "Foradil", Giba- Geigy Product information, (19930000), XP055732678
OPPOSITION- Anonymous, "Foradil", Giba- Geigy - Product Information, (19930000), XP055732678
OPPOSITION- A. PRAKASH et al., "Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combinationwith indacaterol maleate for the treatment of COPD", International Journal of COPD, (20150000), vol. 10, pages 111 - 123, XP055732938
OPPOSITION- "Beta-Adrenoceptor populations", BARNES P J et al., Asthma. Basic Mechanisms and Clinical Management, ACADEMIC PRESS, (19980000), pages 651 - 676, XP055770824
OPPOSITION- CALVO G M et al., "I S IT USEFUL TO ADD AN ANTICHOLINERGIC TREATMENT TO BE T A2-ADRENERGIC MEDICATION IN ACUTE ASTHMA ATTACK", J OURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNGLGGY, (19980100), vol. 8, no. 1, pages 30 - 34, XP009018610
OPPOSITION- D.P. TASHKIN et al., "The Role of Long-Acting Bronchodilators in the Management of Stable COPD*", Chest, (20040000), vol. 125, no. 1, pages 249 - 259, XP055733085
OPPOSITION- ED. ZAAGSMA J et al., "The role of anticholinergics in asthma and COPD", Muscarinic Receptors in Airway Disease, Basel, Switzerland, (20010000), XP055732699
OPPOSITION- Ema, "Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)", EMA/CHMP/483572/2012 -corr1, (20120621), pages 1 - 17, EMA/CHMP/483572/2012 -corr1 , URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf, (20231211), XP093110644
OPPOSITION- Ema, "Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD)", EMA - Clinical Investigation, (19990519), pages 1 - 3, EMA - Clinical Investigation, (20231211), XP093110642
OPPOSITION- Fda, "CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW(S)", CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION. APPLICATION NUMBER: 207930Orig1s000, (20150224), CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION. APPLICATION NUMBER: 207930Orig1s000, (20231211), XP093110646
OPPOSITION- "For COPD a Combination of Ipratropium Bromide and Albuterol Sulfate Is More Effective Than Albuterol Base", Arch Intern Med., (19990125), vol. 159, no. 2, pages 156 - 160, XP0557343190
OPPOSITION- G.M. CALVO et al., "is it user to add an anticholinergic treatment to beta 2-adrenergic medication in acute asthma attack?", J. Investig. Allergol. Clin. Immunol., (19980000), vol. 8, no. 1, pages 30 - 34, XP055732912
OPPOSITION- G WESSELING et al., "A comparison of the effects of anticholinergic and beta 2-agonist and combination therapy on respiratory impedance in COPD", Chest, (19920100), vol. 1 01, no. 1, pages 166 - 73, XP000913861
OPPOSITION- G. WESSELING et al., "A Comparison of the Effects of Anticholinergic and p2-Agonist andCombination Therapy on Respiratory Impedance in CORD", Chest, (19920000), vol. 101, pages 166 - 173, XP055732917
OPPOSITION- Hall et al., "Chapter 36 & 37", Hall et al., P. J. BARNES et al., ASTHMA - BASIC MECHANISMS AND CLINICAL MANAGEMENT, 3rd ed., (19980000), pages 651 - 688, XP055742989
OPPOSITION- "In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial.", COMBIVENT Inhalation Aerosol Study Group, Chest, (19940000), vol. 105, pages 1411 - 1419, XP009010452
OPPOSITION- "Indacaterol maleate", CID 9827599, (20100510), Database accession no. PUBCHEM, URL: https://pubchem.ncbi.nlm.nih .gov/ compound/Indacaterol-maleate, XP055771419
OPPOSITION- J. ZAAGSMA et al., Muscarinic Receptors in Airway Disease, (20010000), pages 203 - 219, 221 to 258, XP055732699
OPPOSITION- KUME et al., "Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle", Eur Respir J, (20120000), XP055732689
OPPOSITION- Malcolm Johnson, "Mechanisms of action of 2-adrenoceptor agonists", Asthma and Rhinitis, (20000000), pages 1541 - 1557, XP055732744
OPPOSITION- Marino et al., "Scientific evidence and expert clinical opinion for the selection and use of bronchodilators: clinical decision making in the individual patient", Marino et al., J. WEDZICHA et al., THE EFFECTIVE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,, (20010000), pages 3 - 23, XP002659229
OPPOSITION- Michael E. Aulton, "Pulmonary drug delivery", Pharmaceutics, The Science of Dosage Form Design, (20020000), XP055732751
OPPOSITION- N. HORITA et al., "Role of combined indacaterol and glycopyrronium bromide (QVAI49) for the treatment of COPD in Japan", International Journal of COPD, (20150000), vol. 10, pages 813 - 822, XP055733088
OPPOSITION- Novartis, "Ultibro Breezehaler 85 micrograms/43 micrograms inhalation powder hard capsules", EMA ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (2013-09-19), XP055770820
OPPOSITION- "Once-daily QVA149 demonstrates superior improvements in lung function compared to tiotrapium plus forrrialerol", Abstracts from the QUANTIFY phase III study
OPPOSITION- "Orciprenaline", Wikipedia, (20200619), URL: https://en.wikipedia.org/w/index.php?title=Orciprenaline&oldid=963440723, XP055767691
OPPOSITION- Peter J. Barnes, "Chapter 11 - Airway Pharmacology", Peter J. Barnes, John F. Murray et al., TEXTBOOK OF RESPIRATORY MEDICINE, 3rd ed., (20000000), pages 267 - 296, XP055742983
OPPOSITION- "Pocket Guide to COPD Diagnosis, Management and Prevention", Global Initiative for Chronic Obstructive Lung Disease, (20110000), XP055732682
OPPOSITION- "Pocket Guide to COPD Diagnosis, Management and Prevention", Global Initiative for Chronic Obstructive Lung Disease (GOLD, (20040000), XP055732681
OPPOSITION- R. DAHL et al., "efficact and safety of QVAI 49 compared to the concurrent administration of its monocomponents indacaterol and glycopyrrionium the BEACON study", International Journal of COPD, (20130000), vol. 8, pages 501 - 508, XP055732882
OPPOSITION- Results of BLAZE phase III study
OPPOSITION- Results of ENLIGHTEN phase III study
OPPOSITION- Results of SPARK phase III study
OPPOSITION- R. K. CYDULKA et al., "Effects of Combined Treatment With Glycopyrrolate and Albuterol in Acute Exacerbation of Chronic Obstructive Pulmonary Disease", Annals of Emergency Medicine, (19950000), vol. 25, no. 4, pages 470 - 473, XP000979833
OPPOSITION- R.K. CYDULKA et al., "EFFECTS OF COMBINED TREATMENT WITH GLYCOPYRROLATE AND ALBUTEROL IN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE", Annals of Emergency Medicine, (19950000), vol. 25, no. 4, pages 470 - 473, XP000979833
OPPOSITION- R K CYDULKA et al., "Effects of Combined Treatment With Glycopyrrolate and Albuterol in Acute Exacerbation of Chronic Obstructive Pulmonary Disease", Ann Emerg Med, (19950400), vol. 25, no. 4, pages 470 - 3, XP000979833
OPPOSITION- R Rutkowski ,M Kazberuk, Z Siergiejko, S Chyrek-Borowska, "Effect of fenoterol, ipratropium bromide and combination drug-berodual-on selected clinical parameters and lung function in patients with asthma", Pneumonol Alergol Pol., vol. 62, no. 7-8, (19940000), pages 358 - 64, URL: https://www.ncbi.nlm.nih.gov/pubmed/7951083, XP055734225
OPPOSITION- "S-3 Invasive Beatmung und Einsatz extra- korporaler Verfahren bei acuter respiratorischer Insuffizienz", German Medical Treatment Guideline, (20171204), XP055771381
OPPOSITION- "Salbutamol", Wikipedia, (20200826), URL: https://en.wikipedia.org/w/index.php?title=Salbutamol&oldid=975076806, XP055767693
OPPOSITION- SALPETER, "cardiovascular safety of b2-adrenoceptor agonist use in patients with obstructive airway disease", Drugs Aging, (20040000), vol. 21, no. 6, pages 405 - 414, XP055732755
OPPOSITION- SICHLETIDIS L. et al., "Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD", Int J Clin Pract., (19990400), vol. 53, no. 3, pages 185 - 188, XP055734313
OPPOSITION- S.I. Rennard, "Chapter 9 - Anticholinergics and [beta]2-agonists: efficacy, safety and combination therapy in chronic obstructive pulmonary disease", S.I. Rennard, P. J. BARNES et al., THE ROLE OF ANTICHOLINERGICS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC ASTHMA, (19980000), pages 137 - 144, XP055742993
OPPOSITION- "The role of anticholinergics in asthma and COPD", ED. J. ZAAGSMA et al., Muscarinic Receptors in Airway Disease, Basel, Switzerland, Birkhäuser, (20010000), pages 203 - 258, XP055732699
OPPOSITION- "The role of anticholinergics in asthma and COPD", J. ZAAGSMA et al., Muscarinic Receptors in Airway Disease, Basel , Switzerland, Birkhauser Verlag, (20010400), vol. 98, pages 203 - 258, XP055732699
OPPOSITION- "The role of anticholinergics in asthma and COPD", Muscarinic Receptors in Airway Disease, Basel, Switzerland, (20010000), pages 203219,221 - 258, XP055732699
OPPOSITION- T.W. GREEN et al., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 2n ed., (19910000), pages 47 - 49, XP002918777
OPPOSITION- VOGELMEIER et al., "Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study", THE LANCET, (20121206), URL: www.thelancet.com/respiratory, XP055732764
OPPOSITION- WESSELING G; MOSTERT R; WOUTERS E F M, "A comparison of the Effects of Anticholinergic and B2-agonist and combination therapy on respiratory impedance in COPD", Chest, (19920000), vol. 101, pages 166 - 73, XP000913861
OPPOSITION- X.-M. ZENG et al., "chapter 5", PARTICLE INTERACTIONS IN DRY POWDER FORMULATIONS FOR INHALATION, London and New York, (20010000), pages 133 - 173, XP055732888
OPPOSITION- M CAZZOLA et al., "Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD", Pulm Pharmacol The r, (19990000), vol. 12, no. 4, doi:10.1006/pupt.1999.0208, pages 267 - 71, XP002210290
OPPOSITION- R K Elwood, R T Abboud, "The short-term bronchodilator effects of fenoterol and ipratropium in asthma", From the Respiratory Division, Department of Medicine, Vancouver, B.C., USA, (19820500), vol. 69, no. 5, pages 467 - 473, XP055734195
OPPOSITION- BACULARD A, "PLACE DU BRONCHODUAL DANS LE TRAITEMENT DE FOND DE L 'ASTHME DE L 'ENFANT BRONCHODUAL IN THE LONG-TERM TREATMENT OF CHILDREN WITH ASTHMA", ARCHIVES DE PEDIATRIE, (19950000), vol. 2, no. SUPPL 2, doi:10.1016/0929-693X(96)89883-6, pages 149S - 153S, XP009010409
OPPOSITION- Melani Andrea S., Bonavia Marco, Cilenti Vincenzo, Cinti Cristina, Lodi Marco, Martucci Paola, Serra Maria, Scichilone Nicola, Sestini Piersante, Aliani Maria, Neri Margherita, "Inhaler mishandling remains common in real life and is associated with reduced disease control", Respiratory Medicine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20110601), vol. 105, no. 6, doi:10.1016/j.rmed.2011.01.005, ISSN 0954-6111, pages 930 - 938, XP093305841
OPPOSITION- BARNES P. J. et al., Basic Mechanisms and Clinical Management, (19980000), XP029004010
OPPOSITION- Donald P. Tashkin, Fernando J. Martinez, Roberto Rodriguez-Roisin, Charles Fogarty, Mark Gotfried, Michael Denenberg, Gregory Gottschlich, James F. Donohue, Chad Orevillo, Patrick Darken, Earl St Rose, Shannon Strom, Tracy Fischer, Michael Golden, Colin Reisner, "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD", Respiratory Medicine, (20160917), vol. 120, doi:10.1016/j.rmed.2016.09.012, pages 16 - 24, XP029802077
OPPOSITION- H.K. CHAN et al., "Novel alternative methods for the delivery of drugs for the treatment of asthma", Advanced Drug Delivery Reviews, (20030000), vol. 55, pages 793 - 805, XP055075721
OPPOSITION- T. SRICHANA et al., "On the relationship between drug and carrier deposition from dry powder inhalers in vitro", Int. J. Pharm., (19980000), vol. 167, pages 13 - 23, XP055732902
OPPOSITION- D.D. BRIGGS et al., "Long-term pharmacologicmanagement of patients with chronic obstructive pulmonary disease", Clinical Cornerstone, (20040206), pages 17 - 28, XP004825197
OPPOSITION- DICK D BRIGGS JR et al., "Long-term pharmacologic management of patients with chronic obstructive pulmonary disease", Clin Cornerstone, (20040000), vol. 6, no. 2, pages S17 - S28, XP026049117
OPPOSITION- R.C. TENNANT et al., "Long-acting p2-adrenoceptor agonists or tiotropium bromidefor patients with COPD: is combination therapy justified?", Curr Opin Pharmacol, (20030000), vol. 3, pages 270 - 278, XP055529479
OPPOSITION- P. LUCAS et al., "PROTEIN DEPOSITION FROM DRY POWDER INHALERS: FINE PARTICLE MULTIPLETS AS PERFORMANCE MODIFIERS", Pharm. Res., (19980000), vol. 15, no. 4, pages 562 - 569, XP001031594
OPPOSITION- J.A. VAN NOORD et al., "Long-term treatment of chronic obstructive pulmonary diseasewith salmeterol and the additive effect of ipratropium", Eur. Respir. J., (20000000), vol. 15, pages 878 - 885, XP001021107
OPPOSITION- J A VAN NOORD et al., "Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium", Eur Respir J, (20000500), vol. 15, no. 5, doi:10.1034/j.1399-3003.2000.15e11.x, pages 878 - 85, XP001021107
OPPOSITION- B.G. BENDER, "Overcoming barriers to nonadherence in asthma treatment", J Allergy Clin Immunol, (20020000), vol. 109, pages S554 - S559, XP055733102
OPPOSITION- Weers Jeffry G., Clark Andrew R., Rao Nagaraja, Ung Keith, Haynes Alfred, Khindri Sanjeev K., Perry Sheryl A., Machineni Surendra, Colthorpe Paul, "In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler ®", Journal of aerosol medicine and pulmonary drug delivery, Mary Ann Liebert, Inc. Publishers, US, US , (20150801), vol. 28, no. 4, doi:10.1089/jamp.2014.1178, ISSN 1941-2711, pages 268 - 280, XP093110640
OPPOSITION- BATTRAM C ET AL., "IN VITRO AND IN VIVO PHARMACOLOGICAL CHARACTERIZATION OF 5-((R)-2-(5,6-DIETHYL-INDAN-2-YLAMINO)-1-HYDROXY-ETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE (INDACATEROL), A NOVEL INHALED BETA2 ADRENORECEPTOR AGONIST WITH A 24-H DURATION OF ACTION", Journal of pharmacology and experimental therapeutics, American Society for Pharmacology and Experimental Therapeutics, US, US , (20060101), vol. 317, no. 2, doi:10.1124/jpet.105.098251, ISSN 0022-3565, pages 762 - 770, XP009077149
OPPOSITION- DAHL et al., "Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD", Thorax, (20100000), vol. 65, pages 473 - 479, XP055732862
OPPOSITION- Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R, "The inhalation device influences lung deposition and bronchodilating effect of terbutaline.", American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, US, US , (19960501), vol. 153, no. 5, doi:10.1164/ajrccm.153.5.8630614, ISSN 1073-449X, pages 1636 - 1640, XP093110636
OPPOSITION- Siddiqui Mohd Kashif, Shukla Pragya, Jenkins Martin, Ouwens Mario, Guranlioglu Deniz, Darken Patrick, Biswas Mousumi, "Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β 2 -agonist fixed-dose combinations in COPD", Therapeutic advances in respiratory disease, (20190101), vol. 13, doi:10.1177/1753466619894502, ISSN 1753-4666, page 175346661989450, XP093110637
OPPOSITION- KORNMANN et al., "Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo controlled comparison", Eur. Respir. J., (20110000), vol. 37, pages 273 - 279, XP055732872
OPPOSITION- BATEMAN et al., "Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study", ERJ Express, (20130000), URL: http://erj.ersjournals.com/content/early/2013/05/30/09031936.00200212.full.pdf+html, XP055121340
OPPOSITION- G. TZELEPIS et al., "Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease", European Respiratory Journal, (19960000), vol. 9, doi:10.1183/09031936.96.09010100, pages 100 - 103, XP000979863
OPPOSITION- G TZELEPIS et al., "Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease", Eur Respir J, (19960100), vol. 9, no. 1, doi:10.1183/09031936.96.09010100, pages 100 - 3, XP000979863
OPPOSITION- G. TZELEPIS et al., "COMPARISON OF NEBULIZED GLYCOPYRROLATE AND METAPROTERENOL IN CHRONIC OBSTRUCTRIVE PULMONARY DISEASE", Eur. Resp. J., (19960000), vol. 9, pages 100 - 103, XP000979863
OPPOSITION- M. PRAT et al., "Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010)", Expert Opin. Ther. Patents, (20110000), vol. 21, no. 10, pages 1543 - 1573, XP055328035
OPPOSITION- M. CAZZOLA et al., "An update on bronchodilators in Phase i and II clinical trials", Expert Opin, Invest. Drugs, (20120000), vol. 21, no. 10, pages 1489 - 1501, XP009185950
OPPOSITION- M. CAZZOLA et al., "An update on bronchodilators in Phase i and II clinical trials", Expert Opin. Invest Drugs, (20120000), vol. 21, no. 10, pages 1489 - 1501, XP009185950
OPPOSITION- Reisner Colin, Pearle James, Kerwin Edward M, St Rose Earl, Darken Patrick, "Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD", The International journal of chronic obstructive pulmonary disease, Albany, Auckland : DOVE Medical Press, Volume 13, doi:10.2147/COPD.S166455, ISSN 1178-2005, pages 1965 - 1977, XP093305843
OPPOSITION- Hurst John R, Gruffydd-Jones Kevin, Biswas Mousumi, Guranlioglu Deniz, Jenkins Martin, Stjepanovic Neda, Bamrara Arushi, "Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons", The International journal of chronic obstructive pulmonary disease, Albany, Auckland : DOVE Medical Press, Volume 15, doi:10.2147/COPD.S230955, ISSN 1178-2005, pages 1529 - 1543, XP093110638
OPPOSITION- M. CAZZOLA et al., "Clinical Pharmacokinetics of Salmeterol", Clin Pharmacokinet, (20020000), vol. 41, no. 1, pages 20 - 30, XP055733090
OPPOSITION- D.E BEAKERS, "The use of anticholinergics in asthma", Journal of Asthma, (19970000), vol. 35, no. 5, pages 357 - 368, XP008057597
OPPOSITION- D.E, BEAKES, "The use of anticholinergics in asthma", Journal of Asthma, (19970000), vol. 34, no. 5, pages 357 - 368, XP008057597
OPPOSITION- D. E. BEAKES, "THE USE OF ANTICHOLINERGICS IN ASTHMA", Journal of Asthma, (19970000), vol. 34, no. 5, pages 357 - 368, XP008057597
OPPOSITION- D.E. BEAKES, "THE USE OF ANTICHOLINERGICS IN ASTHMA", Journal of Asthma, (19970101), vol. 34, no. 5, pages 357 - 368, XP008057597
SEARCH- CALVO G M ET AL, "IS IT USEFUL TO ADD AN ANTICHOLINERGIC TREATMENT TO BETA2-ADRENERGIC MEDICATION IN ACUTE ASTHMA ATTACK", JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, BARCELONA, ES, (199801), vol. 8, no. 1, ISSN 1018-9068, pages 30 - 34, XP009018610 [Y] 1-11 * abstract *
SEARCH- CYDULKA R K ET AL, "EFFECTS OF COMBINED TREATMENT WITH GLYCOPYRROLATE AND ALBUTEROL IN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE", ANNALS OF EMERGENCY MEDICINE, LANSING, MI, US, (199504), vol. 25, ISSN 0196-0644, pages 470 - 473, XP000979833 [Y] 1-11 * abstract *
SEARCH- WESSELING G ET AL, "COMPARISON OF THE EFFECTS OF ANTICHOLINERGIC AND BETA2-AGONIST AND COMBINATION THERAPY ON RESPIRATORY IMPEDANCE IN COPD", CHEST, THE COLLEGE, CHICAGO, IL, US, (1992), vol. 101, no. 1, ISSN 0012-3692, pages 166 - 173, XP000913861 [Y] 1-11 * abstract *
SEARCH- CAZZOLA ET AL, "Incremental Benefit of Adding Oxitropium Bromide to Formoterol in Patients with Stable COPD", PULMONARY PHARMACOLOGY AND THERAPEUTICS, ACADEMIC PRESS, NEW YORK, NY, US, (1999), vol. 12, ISSN 1094-5539, pages 267 - 271, XP002210290 [Y] 1-11 * abstract *
SEARCH- BACULARD A, "PLACE DU BRONCHODUAL DANS LE TRAITEMENT DE FOND DE L'ASTHME DE L'ENFANT BRONCHODUAL IN THE LONG-TERM TREATMENT OF CHILDREN WITH ASTHMA", ARCHIVES DE PEDIATRIE, ELSEVIER, PARIS, FR, (1995), vol. 2, no. SUPPL 2, ISSN 0929-693X, pages 149S - 153S, XP009010409 [Y] 1-11 * abstract *
SEARCH- BRIGGS D D ET AL, "Long-term pharmacologicmanagement of patients with chronic obstructive pulmonary disease", CLINICAL CORNERSTONE, EXCERPTA MEDICA,, GB, (2004), vol. 6, no. 2, ISSN 1098-3597, pages S17 - S28, XP004825197 [Y] 1-11 * abstract * * page S23, paragraph L - page S24, paragraph 2; table VII *
SEARCH- NOORD VAN J A ET AL, "LONG-TERM TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH SALMETEROL AND THE ADDITIVE EFFECT OF IPRATROPIUM", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, (200005), vol. 15, no. 5, ISSN 0903-1936, pages 878 - 885, XP001021107 [Y] 1-11 * abstract *
SEARCH- TZELEPIS G ET AL, "COMPARISON OF NEBULIZED GLYCOPYRROLATE AND METAPROTERENOL IN CHRONIC OBSTRUCTRIVE PULMONARY DISEASE", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, (1996), vol. 9, no. 8, ISSN 0903-1936, pages 100 - 103, XP000979863 [Y] 1-11 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents